CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. (CASI) Revenue
Annual & quarterly revenue history · segment & region breakdown
CASI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCASI Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.03B, a decrease of 15.77% year-over-year from $0.03B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.03B | -$0.01B | -15.77% |
| 2023-12-31 | $0.03B | -$0.01B | -21.41% |
| 2022-12-31 | $0.04B | +$0.01B | +42.89% |
| 2021-12-31 | $0.03B | +$0.02B | +99.25% |
| 2020-12-31 | $0.02B | +$0.01B | +266.52% |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | -$0.00B | -100.00% |
| 2015-12-31 | $0.00B | +$0.00B | +101.09% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CASI Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CASI Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from CASI Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CASI revenue · 4 questionsCASI's trailing twelve-month (TTM) revenue is $0.03B. That is a decrease of 15.77% year-over-year from $0.03B in FY2024.
▸ Source: FMP · CASI Pharmaceuticals, Inc. SEC filings · GAAP · CASI Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026